Sensus Healthcare, Inc. (NASDAQ:SRTS) Stock Position Cut by Two Sigma Investments LP

Two Sigma Investments LP lessened its stake in Sensus Healthcare, Inc. (NASDAQ:SRTS) by 41.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 90,523 shares of the company’s stock after selling 63,521 shares during the period. Two Sigma Investments LP owned 0.55% of Sensus Healthcare worth $626,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its position in shares of Sensus Healthcare by 30.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 378,568 shares of the company’s stock valued at $2,620,000 after purchasing an additional 88,953 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of Sensus Healthcare by 81.2% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 150,150 shares of the company’s stock valued at $1,039,000 after purchasing an additional 67,269 shares in the last quarter. Marshall Wace LLP boosted its position in shares of Sensus Healthcare by 99.6% during the 4th quarter. Marshall Wace LLP now owns 132,286 shares of the company’s stock valued at $915,000 after purchasing an additional 65,994 shares in the last quarter. Millennium Management LLC boosted its position in shares of Sensus Healthcare by 256.6% during the 4th quarter. Millennium Management LLC now owns 85,329 shares of the company’s stock valued at $590,000 after purchasing an additional 61,403 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp bought a new position in shares of Sensus Healthcare during the 4th quarter valued at about $381,000. Institutional investors own 25.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Sensus Healthcare in a report on Friday, April 4th. Wall Street Zen cut shares of Sensus Healthcare from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Maxim Group decreased their target price on shares of Sensus Healthcare from $14.00 to $10.00 and set a “buy” rating for the company in a report on Monday, May 19th. Finally, Lake Street Capital decreased their price target on shares of Sensus Healthcare from $18.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Sensus Healthcare currently has an average rating of “Moderate Buy” and an average target price of $11.67.

Sensus Healthcare Stock Performance

SRTS stock opened at $4.92 on Monday. The stock has a market cap of $80.91 million, a P/E ratio of 12.30 and a beta of 1.32. The firm has a 50 day simple moving average of $4.63 and a 200 day simple moving average of $5.85. Sensus Healthcare, Inc. has a 52 week low of $4.01 and a 52 week high of $9.33.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.20). The company had revenue of $8.34 million for the quarter, compared to analyst estimates of $7.23 million. Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. Sell-side analysts predict that Sensus Healthcare, Inc. will post 0.32 EPS for the current year.

Sensus Healthcare Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.